PMID- 21595034
OWN - NLM
STAT- MEDLINE
DCOM- 20110920
LR  - 20230612
IS  - 1615-9861 (Electronic)
IS  - 1615-9853 (Print)
IS  - 1615-9853 (Linking)
VI  - 11
IP  - 12
DP  - 2011 Jun
TI  - Identification and characterization of human leukocyte antigen class I ligands in 
      renal cell carcinoma cells.
PG  - 2528-41
LID - 10.1002/pmic.201000486 [doi]
AB  - The presentation of tumor antigen-derived peptides by human leukocyte antigen 
      (HLA) class I surface antigens on tumor cells is a key prerequisite to trigger 
      effective T-cell responses in cancer patients. Multiple complementary strategies 
      like cDNA and serological expression cloning, reverse immunology and different 
      'ome'-based methods have been employed to identify potential T-cell targets. This 
      report focuses on a ligandomic profiling approach leading to the identification 
      of 49 naturally processed HLA class I peptide ligands presented on the cell 
      surface of renal cell carcinoma (RCC) cells. The source proteins of the defined 
      HLA ligands are classified according to their biological function and subcellular 
      localization. Previously established cDNA microarray data of paired tissue 
      specimen of RCC and renal epithelium assessed the transcriptional regulation for 
      28 source proteins. In addition, HLA-A2-restricted, peptide-specific T cells 
      directed against a HLA ligand derived from sulfiredoxin-1 (SRXN1) were generated, 
      which were able to recognize and lyse ligand-presenting target cells in a HLA 
      class I-restricted manner. Furthermore, tumor-infiltrating T cells isolated from 
      a RCC patient were also able to kill SRXN1 expressing tumor cells. Thus, this 
      experimental strategy might be suited to define potential candidate biomarkers 
      and novel targets for T-cell-based immunotherapies of this disease.
CI  - Copyright (c) 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
FAU - Seliger, Barbara
AU  - Seliger B
AD  - Institute of Medical Immunology, Martin-Luther University Halle-Wittenberg, 
      Halle, Germany. barbara.seliger@medizin.uni-halle.de
FAU - Dressler, Sven P
AU  - Dressler SP
FAU - Massa, Chiara
AU  - Massa C
FAU - Recktenwald, Christian V
AU  - Recktenwald CV
FAU - Altenberend, Florian
AU  - Altenberend F
FAU - Bukur, Juergen
AU  - Bukur J
FAU - Marincola, Francesco M
AU  - Marincola FM
FAU - Wang, Ena
AU  - Wang E
FAU - Stevanovic, Stefan
AU  - Stevanovic S
FAU - Lichtenfels, Rudolf
AU  - Lichtenfels R
LA  - eng
GR  - Z01 CL002118/ImNIH/Intramural NIH HHS/United States
GR  - Z01 CL002118-02/ImNIH/Intramural NIH HHS/United States
GR  - ZIA CL002118/ImNIH/Intramural NIH HHS/United States
GR  - ZIA CL002118-03/ImNIH/Intramural NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110518
PL  - Germany
TA  - Proteomics
JT  - Proteomics
JID - 101092707
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (DNA, Complementary)
RN  - 0 (Epitopes)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Ligands)
RN  - 0 (Neoplasm Proteins)
RN  - EC 1.8.- (Oxidoreductases Acting on Sulfur Group Donors)
RN  - EC 1.8.98.2 (SRXN1 protein, human)
SB  - IM
MH  - Antigens, Neoplasm/genetics/*immunology/metabolism
MH  - Carcinoma, Renal Cell/genetics/*immunology/metabolism
MH  - Chromatography, Liquid
MH  - Cloning, Molecular
MH  - DNA, Complementary/genetics/metabolism
MH  - Epitopes/immunology
MH  - Gene Expression Profiling
MH  - Gene Expression Regulation, Neoplastic
MH  - Histocompatibility Antigens Class I/genetics/*immunology/metabolism
MH  - Humans
MH  - Immunotherapy/methods
MH  - Kidney Neoplasms/genetics/*immunology/metabolism
MH  - Ligands
MH  - Mass Spectrometry
MH  - Neoplasm Proteins/genetics/*immunology/metabolism
MH  - Oligonucleotide Array Sequence Analysis
MH  - Oxidoreductases Acting on Sulfur Group Donors/genetics/*immunology/metabolism
MH  - T-Lymphocytes, Cytotoxic/*immunology/metabolism
MH  - Transcription, Genetic
MH  - Tumor Cells, Cultured
PMC - PMC3517181
MID - NIHMS421463
COIS- The authors have declared no conflict of interest.
EDAT- 2011/05/20 06:00
MHDA- 2011/09/21 06:00
PMCR- 2012/12/07
CRDT- 2011/05/20 06:00
PHST- 2010/08/06 00:00 [received]
PHST- 2011/03/07 00:00 [revised]
PHST- 2011/03/28 00:00 [accepted]
PHST- 2011/05/20 06:00 [entrez]
PHST- 2011/05/20 06:00 [pubmed]
PHST- 2011/09/21 06:00 [medline]
PHST- 2012/12/07 00:00 [pmc-release]
AID - 10.1002/pmic.201000486 [doi]
PST - ppublish
SO  - Proteomics. 2011 Jun;11(12):2528-41. doi: 10.1002/pmic.201000486. Epub 2011 May 
      18.